Bristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat
- Mar 1, 2022
- 1 min read
Updated: Sep 13, 2022
Two years ago, Bristol Myers Squibb R&D boss Rupert Vessey unveiled one of the biggest cash deals he’d done, focusing on the high-risk, high-reward IL-12 target — doing it in a deal with repeat collaborator and NK cell engager player Dragonfly Therapeutics.
As part of that deal, Vessey handed over $475 million in near-term cash in exchange for a global license for Dragonfly’s extended half-life cytokine DF6002 — a monovalent, IL-12 immunoglobulin Fc fusion protein designed to spur a targeted immune response.
Great breakdown of a pretty complex topic — you did a solid job making the science and partnership angle easier to understand. I especially liked how the progress around IL-12 was framed in a broader research context. I came across a similar discussion on a review blog fake degree, which also emphasized how collaboration often drives meaningful advances in biotech.
The ball in Slope run gradually accelerates as the run continues. This natural progression transforms a calm start into a high-pressure scenario.